How Dassault Systèmes SE Is Reducing Pharmaceutical & Drug Development Trial Failure Rates with Digital Twins

Dassault Systèmes SE has entered the digital twins & in silico trials arena with Dassault Systèmes SIMULIA (Living Heart Project), a platform that physics-based virtual human simulation enabling in silico clinical trials for cardiovascular devices and drugs. The move positions the company in a market projected to reach $1.8 billion by 2028, where in silico trials have reduced Phase I costs by 15-30%. Dassault Systèmes SIMULIA develops computational simulation software for physics-based modeling of biological systems, with its Living Heart Project representing the most advanced publicly shared cardiac digital twin platform. The Living Heart Human Model is an anatomically accurate, biophysically detailed finite element model of the human heart that simulates electrical conduction, mechanical contraction, and fluid dynamics simultaneously. For VP Clinical Development and Head of Translational Research professionals evaluating new solutions, the entry adds another option in an increasingly crowded field. The broader context is unmistakable: enterprises are moving beyond experimental AI pilots toward production-grade platforms that integrate with existing infrastructure and deliver measurable ROI from day one.

Simulation Capabilities

For VP Clinical Development and Head of Translational Research professionals, Dassault Systèmes SIMULIA (Living Heart Project) addresses several critical needs. The platform's organ system models capabilities — detailed models of cardiovascular, hepatic, renal, and neural organ systems for pbpk simulation — form the foundation. Layered on top, trial design optimization provides ai-optimized trial design including dosing schedules, endpoints, and patient stratification. Regulatory Evidence Generation extends the platform further, generate computational evidence packages aligned with fda guidance for regulatory submissions. The platform's design reflects a market reality: in silico trials have reduced Phase I costs by 15-30%, and buyers want solutions that deliver quickly. Enterprise buyers in the digital twins & in silico trials space increasingly evaluate platforms on three criteria: time-to-value, integration depth with existing systems, and the ability to demonstrate 25-45% reduction in clinical trial failure rates in controlled pilots before committing to full-scale deployment.

On the integration front, Dassault Systèmes SIMULIA (Living Heart Project) connects with GastroPlus, PK-Sim, Certara Simcyp, COMSOL Multiphysics and 8 additional systems. For digital twins & in silico trials buyers, native connectivity to industry-standard platforms is often the deciding factor — and Dassault Systèmes SE appears to understand this.

Why Virtual Trials Matter

Three years ago, digital twins & in silico trials was a niche category within digital biology. Today, it's a $1.8 billion by 2028 opportunity that every major pharmaceutical & drug development operator is evaluating. The shift has been driven by hard numbers: in silico trials have reduced Phase I costs by 15-30%, and early adopters are reporting 25-45% reduction in clinical trial failure rates. The underlying trend — organ-level digital twins are enabling personalized dosing simulations — shows no signs of slowing. For VP Clinical Development and Head of Translational Research professionals, the question is no longer whether to invest, but which vendor to bet on. This maturation has also changed how vendors compete: the market is moving past the hype cycle and into a phase where platform reliability, integration ecosystem breadth, and demonstrable customer outcomes determine which solutions gain traction. For Dassault Systèmes SE, this means the path to market share runs through proven deployments rather than promises.

Enterprise Considerations

Any digital twins & in silico trials deployment carries inherent risks that pharmaceutical & drug development enterprises should evaluate carefully. Platform maturity, vendor financial stability, and the depth of the integration ecosystem all factor into the decision. Dassault Systèmes SE will be judged by its ability to support enterprise-grade SLAs, handle the data volumes that pharmaceutical & drug development operations generate, and maintain performance during peak demand periods. Smart buyers mitigate these risks through structured pilots, phased rollouts, and contractual performance guarantees that tie vendor compensation to measurable business outcomes.

Looking Forward

Dassault Systèmes SE brings several things to the table: a focus on digital twins & in silico trials, and the tailwinds of a $1.8 billion by 2028 market opportunity that is growing faster than most adjacent categories in AI technology. But it faces stiff competition from Unlearn.AI, Inc., each with established customer bases and production track records that Dassault Systèmes SE will need to match. The risk for buyers: newer platforms may lack the integration depth and battle-tested reliability that enterprise pharmaceutical & drug development operations demand, particularly during peak periods when system failures have outsized consequences. The upside: 25-45% reduction in clinical trial failure rates for those who choose well. The smart approach for VP Clinical Development and Head of Translational Research teams is to run a structured pilot, benchmark against current systems, and make a data-driven decision rather than relying on vendor claims alone.